RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds

ROCKVILLE, Md., March 14, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO)...

Leave a comment

Your email address will not be published.